1. Exact Sciences acquired by Abbott for $21 billion, boosting momentum. 2. Exact Sciences' shares rose 51%, indicating strong recent performance. 3. Haemonetics beat earnings estimates with a 61% monthly stock gain. 4. Both stocks show high RSI values, suggesting overbought conditions.